Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype

Journal of Infectious Diseases

Volumn 174, Issue 4, 1996, Pages 854-857

  Holodniy, Mark ^a   Katzenstein, David ^b   Mole, Larry ^b   Winters, Mark ^b   Merigan, Thomas ^b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CODON; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; MARKER GENE; PHENOTYPE; PRIORITY JOURNAL; SYNCYTIUM; TREATMENT OUTCOME; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0029792776     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.4.854     Document Type: Article

References (15)

1. Loveday C, Kaye S, Tenant-Flowers M, et al. HIV-1 RNA seram-load and resistant viral genotypes during early zidovudine therapy. Lancet 1995;345:820-4.
2. 3. A double-blind randomized, controlled trial. Ann Intern Med 1995;123:561-71.
3. Japour AJ, Welles S, D'Aquila RT, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis 1995;171:1172-9.
4. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995;122:401-8.
5. Hammer SM, Katzenstein DA, Hughes MD, Hirsch MS, Merigan TC, for the ACTG 175 Virology Substudy Team [abstract S24]. Virologie markers and outcome in ACTG 175. In: Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, VA: Infectious Diseseases Society of American, 1996.
6. Choo V. Combination superior to zidovudine in Delta trial [news]. Lancet 1995;346:895.
7. Shafer RW, Iversen AKN, Winters MA, et al. Drug resistance and heterogeneous long-term virologie responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J Infect Dis 1995;172:70-8.
8. Holodniy M, Mole L, Margolis D, et al. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didianosine combination therapy. J Virol 1995;69:3510-6.
9. Kozal MJ, Kroodsma K, Winters MA, et al. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med 1994;121:263-8.
10. St Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-9.
11. Cox SW, Albert J, Wahlberg J, Uhlen M, Wahren B. Loss of synergistic response to combinations containing AZT in AZT-resistant HIV-1. AIDS Res Hum Retroviruses 1992;8:1229-34.
12. Mayers DL, Japour AJ, Arduino JM, et al. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. Antimicrob Agents Chemother 1994;36;307-14.
13. Masquelier B, Pellegrin I, Ruffault A, et al. Genotypic evolution of HIV1 isolates from patients after a switch of therapy from zidovudine to didanosine. J AIDS 1995;8:330-45.
14. Caliendo AM, Savara A, An D, DeVore K, Kaplan JC, D'Aquila RT. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J Virol 1996;70:2146-53.
15. Shafer RW, Kozal MJ, Winters MA, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis 1994;169;722-9.